Top-End Earnings Momentum Analytics Raise Ranking of Humana (HUM) to Strong Buy

HUM stock a strong buy in latest weekly rating.

 
 

Currently, Humana Inc (NYSE:HUM) has a Strong Buy using Louis Navellier’s methods for investing and his Portfolio Grader stock evaluator. The shares have been upgraded from a Buy to a Strong Buy in the last week.

HUM is a $37.4 billion in market value constituent of the Health Care Providers & Services GICS industry group where the stock’s Portfolio Grader ranking places it 11 among the 82 companies in this industry group, putting in the top quartile. HUM is ranked in the top decile of the sector with a ranking of 51 among the 783 companies in the sector of its Health Care sector and 370 in the Portfolio Grader company universe.

Portfolio Grader currently ranks the Health Care sector number 10 among the 12 sectors in its universe putting it in the bottom quartile of all the GICS sectors. The Health Care Providers & Services industry group is ranked 35 among the 69 industry groups within the GICS sectors, placing it below-average in terms of the Navellier scoring system.

Humana has realized above-average scores in 6 of the 8 fundamental areas appraised by Portfolio Grader in the ranking of company stocks.

HUM’s operational scores provide mixed results with rankings for operating margin and earnings growth that are well above average, while the score for sales growth is below average. Scores for visibility of earnings are superior with a ranking for earnings revisions, earnings surprises and earnings momentum that are discernibly better than average. HUM’s score for return on equity is much better than its industry group average but its grade for cash flow is below-average. These fundamental scores give Humana a position in the top decile of the industry group.

Portfolio Grader uses the Navellier Proprietary Quantitative Score to view HUM’s shares from the aspect of risk/reward. This unique scoring system takes into account the relative value of the company’s shares based on the current price of the shares relative to its peers, the market and risk associated with its industry and sector groups. Using this risk/reward calculation, HUM currently scores well above-average in its industry group compared to its peers.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results, with A being ‘strong buy’ and F being ‘strong sell’. Explore the tool here.

Commentary provided by UpTick Data Technologies.


Article printed from InvestorPlace Media, https://investorplace.com/2017/11/top-end-earnings-momentum-analytics-raise-ranking-of-humana-hum-to-strong-buy/.

©2017 InvestorPlace Media, LLC

Value-Based Care: Dr. Chauhan | Humana


Dr. Chauhan discusses the benefits of his value-based care partnership with Humana.

Subscribe to the Humana YouTube Channel

For 50 years, Humana, headquartered in Louisville, Kentucky, has been an innovator with a commitment to service, health and wellness. Our focus on people, choice, engagement and innovation guides our business practices and decision-making. In addition to group health plans, Humana’s diverse lines of business position us to serve millions of people with a wide range of needs, including seniors, military members and self-employed individuals.

Website:
Facebook:
Twitter:
Google+:

Which is the Better Investment? – Stock News Gazette

UnitedHealth Group Incorporated (NYSE:UNH) shares are up more than 30.92% this year and recently decreased -0.33% or -$0.69 to settle at $209.53. Humana Inc. (NYSE:HUM), on the other hand, is up 25.22% year to date as of 11/01/2017. It currently trades at $255.48 and has returned 2.87% during the past week.

UnitedHealth Group Incorporated (NYSE:UNH) and Humana Inc. (NYSE:HUM) are the two most active stocks in the Health Care Plans industry based on today’s trading volumes. The market is clearly enthusiastic about both these stocks, but which is the better investment? To answer this, we will compare the two companies based on the strength of their growth, profitability, risk, returns, valuation, analyst recommendations, and insider trends.

Growth

The ability to consistently grow earnings at a high compound rate is a defining characteristic of the best companies for long-term investment. Analysts expect UNH to grow earnings at a 14.88% annual rate over the next 5 years. Comparatively, HUM is expected to grow at a 13.32% annual rate. All else equal, UNH’s higher growth rate would imply a greater potential for capital appreciation.

Profitability and Returns

Growth isn’t very attractive to investors if companies are sacrificing profitability and shareholder returns to achieve that growth. We will use EBITDA margin and Return on Investment (ROI), which control for differences in capital structure between the two companies, to measure profitability and return., compared to an EBITDA margin of 7.09% for Humana Inc. (HUM). UNH’s ROI is 11.40% while HUM has a ROI of 5.40%. The interpretation is that UNH’s business generates a higher return on investment than HUM’s.

Cash Flow 

The amount of free cash flow available to investors is ultimately what determines the value of a stock. UNH’s free cash flow (“FCF”) per share for the trailing twelve months was +6.42. Comparatively, HUM’s free cash flow per share was -1.88. On a percent-of-sales basis, UNH’s free cash flow was 3.36% while HUM converted -0.5% of its revenues into cash flow. This means that, for a given level of sales, UNH is able to generate more free cash flow for investors.

Financial Risk

UNH’s debt-to-equity ratio is 0.74 versus a D/E of 0.47 for HUM. UNH is therefore the more solvent of the two companies, and has lower financial risk.

Valuation

UNH trades at a forward P/E of 19.35, a P/B of 4.68, and a P/S of 1.03, compared to a forward P/E of 20.78, a P/B of 3.37, and a P/S of 0.69 for HUM. UNH is the cheaper of the two stocks on an earnings basis but is expensive in terms of P/B and P/S ratio. Given that earnings are what matter most to investors, analysts tend to place a greater weight on the P/E.

Analyst Price Targets and Opinions

Just because a stock is cheaper doesn’t mean there’s more value to be had. In order to assess value we need to compare the current price to where it’s likely to trade in the future. UNH is currently priced at a -8.61% to its one-year price target of 229.26. Comparatively, HUM is -3.86% relative to its price target of 265.73. This suggests that UNH is the better investment over the next year.

The average investment recommendation on a scale of 1 to 5 (1 being a strong buy, 3 a hold, and 5 a sell) is 1.50 for UNH and 1.90 for HUM, which implies that analysts are more bullish on the outlook for HUM.

Risk and Volatility

No discussion on value is complete without taking into account risk. Analysts use a stock’s beta, which measures the volatility of a stock compared to the overall market, to measure systematic risk. A stock with a beta above 1 is more volatile than the market. Conversely, a beta below 1 implies a below average level of risk. UNH has a beta of 0.64 and HUM’s beta is 0.89. UNH’s shares are therefore the less volatile of the two stocks.

Insider Activity and Investor Sentiment

Comparing the number of shares sold short to the float is a method analysts often use to get a reading on investor sentiment. UNH has a short ratio of 2.86 compared to a short interest of 3.45 for HUM. This implies that the market is currently less bearish on the outlook for UNH.

Summary

UnitedHealth Group Incorporated (NYSE:UNH) beats Humana Inc. (NYSE:HUM) on a total of 11 of the 14 factors compared between the two stocks. UNH is growing fastly, is more profitable, generates a higher return on investment, has higher cash flow per share, has a higher cash conversion rate and higher liquidity. UNH is more undervalued relative to its price target. Finally, UNH has better sentiment signals based on short interest.

Humana (HUM) and The Competition Head to Head Analysis

Humana (NYSE: HUM) is one of 14 public companies in the “Managed Health Care” industry, but how does it weigh in compared to its rivals? We will compare Humana to related businesses based on the strength of its dividends, profitability, analyst recommendations, institutional ownership, valuation, earnings and risk.

Profitability

This table compares Humana and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Humana 3.37% 15.85% 5.76%
Humana Competitors 1.77% 10.69% 3.47%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Humana and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Humana 0 8 12 0 2.60
Humana Competitors 79 884 1444 23 2.58

Humana presently has a consensus target price of $253.11, indicating a potential downside of 0.88%. As a group, “Managed Health Care” companies have a potential downside of 3.29%. Given Humana’s stronger consensus rating and higher probable upside, analysts clearly believe Humana is more favorable than its rivals.

Insider & Institutional Ownership

95.8% of Humana shares are owned by institutional investors. Comparatively, 90.3% of shares of all “Managed Health Care” companies are owned by institutional investors. 0.8% of Humana shares are owned by company insiders. Comparatively, 2.4% of shares of all “Managed Health Care” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

Humana has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500. Comparatively, Humana’s rivals have a beta of 0.77, indicating that their average stock price is 23% less volatile than the S&P 500.

Earnings & Valuation

This table compares Humana and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Humana $53.87 billion $2.66 billion 20.84
Humana Competitors $52.70 billion $3.80 billion 16.97

Humana has higher revenue, but lower earnings than its rivals. Humana is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Dividends

Humana pays an annual dividend of $1.60 per share and has a dividend yield of 0.6%. Humana pays out 13.1% of its earnings in the form of a dividend. As a group, “Managed Health Care” companies pay a dividend yield of 0.9% and pay out 20.3% of their earnings in the form of a dividend. Humana has raised its dividend for 6 consecutive years.

Summary

Humana beats its rivals on 11 of the 15 factors compared.

Humana Company Profile

Humana Inc. is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products. The Group and Specialty segment consists of employer group commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health. The Healthcare Services segment includes services offered to its health plan members, as well as to third parties, including pharmacy solutions, provider services, home-based services and clinical programs, as well as services and capabilities to manage population health. The Individual Commercial segment includes Individual Commercial products marketed under the HumanaOne brand.

Receive News & Ratings for Humana Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Humana Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Humana (NYSE:HUM) Earning Somewhat Favorable News Coverage, Analysis Shows

News articles about Humana (NYSE:HUM) have been trending somewhat positive on Thursday, Accern reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Humana earned a news impact score of 0.19 on Accern’s scale. Accern also gave headlines about the insurance provider an impact score of 46.3006491209818 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Here are some of the news headlines that may have effected Accern Sentiment’s analysis:

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.08 by $0.41. Humana had a net margin of 3.37% and a return on equity of 15.85%. The firm had revenue of $13.53 billion for the quarter, compared to the consensus estimate of $13.61 billion. During the same period last year, the firm earned $2.30 earnings per share.

The business also recently declared a dividend, which was paid on Monday, October 16th. Shareholders of record on Friday, September 29th were issued a $0.40 dividend. The ex-dividend date was Thursday, September 28th. Humana’s dividend payout ratio is currently 13.06%.

A number of research analysts recently weighed in on HUM shares. BidaskClub raised Humana from a “sell” rating to a “hold” rating in a research note on Wednesday, August 23rd. ValuEngine lowered Humana from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. Jefferies Group LLC reissued a “hold” rating and set a $257.00 price objective on shares of Humana in a report on Friday, October 13th. J P Morgan Chase & Co lowered Humana from an “overweight” rating to a “neutral” rating and set a $253.00 price objective for the company. in a report on Monday, October 9th. Finally, Royal Bank Of Canada reissued a “hold” rating and set a $245.00 price objective on shares of Humana in a report on Tuesday, October 10th. Twelve equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $253.90.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://ledgergazette.com/2017/11/02/humana-hum-given-media-sentiment-score-of-0-19.html.

In related news, VP Timothy S. Huval sold 7,803 shares of the firm’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $258.14, for a total transaction of $2,014,266.42. Following the sale, the vice president now owns 8,831 shares in the company, valued at $2,279,634.34. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider William Kevin Fleming sold 3,071 shares of Humana stock in a transaction dated Wednesday, August 23rd. The shares were sold at an average price of $250.98, for a total transaction of $770,759.58. Following the completion of the sale, the insider now owns 7,681 shares in the company, valued at approximately $1,927,777.38. The disclosure for this sale can be found here. In the last ninety days, insiders sold 55,595 shares of company stock valued at $14,133,706. Corporate insiders own 0.80% of the company’s stock.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Insider Buying and Selling by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Humana Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Humana (NYSE:HUM) vs. The Competition Financial Survey

Humana (NYSE: HUM) is one of 14 publicly-traded companies in the “Managed Health Care” industry, but how does it weigh in compared to its rivals? We will compare Humana to related companies based on the strength of its profitability, dividends, risk, valuation, earnings, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares Humana and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Humana $53.87 billion $2.66 billion 20.84
Humana Competitors $52.70 billion $3.80 billion 18.38

Humana has higher revenue, but lower earnings than its rivals. Humana is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

95.8% of Humana shares are owned by institutional investors. Comparatively, 90.3% of shares of all “Managed Health Care” companies are owned by institutional investors. 0.8% of Humana shares are owned by insiders. Comparatively, 2.5% of shares of all “Managed Health Care” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility and Risk

Humana has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500. Comparatively, Humana’s rivals have a beta of 0.76, indicating that their average share price is 24% less volatile than the S&P 500.

Profitability

This table compares Humana and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Humana 3.37% 15.85% 5.76%
Humana Competitors 1.70% 10.28% 3.36%

Analyst Recommendations

This is a breakdown of recent ratings for Humana and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Humana 0 8 12 0 2.60
Humana Competitors 79 883 1443 23 2.58

Humana currently has a consensus target price of $253.11, suggesting a potential downside of 0.88%. As a group, “Managed Health Care” companies have a potential downside of 3.82%. Given Humana’s stronger consensus rating and higher possible upside, analysts plainly believe Humana is more favorable than its rivals.

Dividends

Humana pays an annual dividend of $1.60 per share and has a dividend yield of 0.6%. Humana pays out 13.1% of its earnings in the form of a dividend. As a group, “Managed Health Care” companies pay a dividend yield of 0.9% and pay out 20.7% of their earnings in the form of a dividend. Humana has raised its dividend for 6 consecutive years.

Summary

Humana beats its rivals on 11 of the 15 factors compared.

Humana Company Profile

Humana Inc. is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products. The Group and Specialty segment consists of employer group commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health. The Healthcare Services segment includes services offered to its health plan members, as well as to third parties, including pharmacy solutions, provider services, home-based services and clinical programs, as well as services and capabilities to manage population health. The Individual Commercial segment includes Individual Commercial products marketed under the HumanaOne brand.




Receive News & Ratings for Humana Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Humana Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

theRacetotheBottom – Home – The Director Compensation Project: Humana, Inc. (HUM)

This post is part of an ongoing series that examines the way stock exchange independence rules relate to director compensation. We are for the most part including companies from 2017’s Fortune 500 and using information found in their 2017 proxy statements.

NASDAQ and the NYSE have similar rules with respect to director independence. NYSE Rule 303A.01 requires that each listed company’s board of directors be comprised of a majority of independent directors. A director does not qualify as “independent” if he or she has a “material relationship with the company.” NYSE Rule 303A.02(a). In addition, the director is not considered independent under NYSE Rule 303A.02(b)(ii) if the director received more than $120,000 in direct compensation, other than director’s fees, during any of the previous three years. The NYSE imposes a higher independence standard for directors serving on the company’s audit committee by requiring them to comport with Rule 10A-3 (C.F.R. §240.10A-3) (see Rule 303A.06) and requires consideration by the board of directors of certain specified factors in designating directors for the Compensation Committee. See NYSE Rule 303A.02(a)(ii).

Finally, as the Commission has noted with respect to director independence:

All compensation committee members must meet the general independence standards under NYSE’s rules in addition to the two new criteria being adopted herein. The Commission therefore expects that boards, in fulfilling their obligations, will apply this standard to each such director’s individual responsibilities as a board member, including specific committee memberships such as the compensation committee. Although personal and business relationships, related party transactions, and other matters suggested by commenters are not specified either as bright-line disqualifications or explicit factors that must be considered in evaluating a director’s independence, the Commission believes that compliance with NYSE’s rules and the provision noted above would demand consideration of such factors with respect to compensation committee members, as well as to all Independent Directors on the board.

Exchange Act Release No. 68639 (Jan. 11, 2013); see also Exchange Act Release No. 68641 (Jan. 11, 2013).

Independent directors are compensated for their service on the board. The amount of “total compensation” can be seen from examining the director compensation table from the Humana Inc. (NYSE: HUM) 2017 proxy statement. According to the proxy statement, the company paid the directors the following amounts:

Name

Fees Earned or Paid in Cash

($)

Stock Awards

($)

Option Awards

($)

All Other Compensation

($)

Total

($)

Frank A. D’Amelio

130,000

154,999

0

11,406

296,405

W. Roy Dunbar

117,000

154,999

0

7,283

279,282

Kurt J. Hilzinger

302,000

154,999

0

27,072

484,072

David A. Jones, Jr.

129,000

154,999

0

25,788

315,072

William J. McDonald

123,000

154,999

0

28,765

306,764

William E. Mitchell

105,000

154,999

0

27,125

287,124

David B. Nash, M.D.

105,000

154,999

0

26,113

286,112

James J. O’Brien

105,000

154,999

0

27,397

287,396

Marissa T. Peterson

105,000

154,999

0

22,476

282,475

Bruce D. Broussard served as President and Chief Executive Officer and member of the Board of Directors. As an employee director, he did not earn compensation in connection with his service on the Board.

Director Compensation. During fiscal year 2016, Humana Inc. held 19 board of directors’ meetings. Each director attended at least 75% of the total number of board and committee meetings on which he or she served. All directors attended the 2016 Annual Meeting of Shareholders. Directors are reimbursed for expenses incurred from board service, including cost of attending board meetings.

Director Tenure. In 2016, Mr. Jones Jr. held the longest tenure as a member of the Board of Directors since 1993,. Mr. Broussard holds the shortest tenure, having joined in 2013. All but four directors sit on other boards: Mr. Hilzinger serves as a director for Oncobiologics, Inc. and National Seating and Mobility, Inc., Mr. Broussard serves as a member of the Board of Directors for America’s Health Insurance Plans, Mr. D’Amelio serves on the Board of Directors for Zoetis, Inc., Mr. Jones Jr. serves as a director for Connecture, Inc. and MyHealthDirect, Inc., Mr. Mitchell serves as a director for Veritiv, Inc., Mr. Nash serves on the board of Vestagen Specialty Textiles, and Mr. O’Brien serves as a director for Albermarle Corporation, Wesco International, Inc., and Eastman Chemical Company.

CEO Compensation. Mr. Broussard, Humana’s President and Chief Executive Officer earned a total compensation of $19,722,400 in 2016. He earned a base salary of $1,235,446, stock awards of $11,888,551, option awards of $4,370,743, non-equity incentive plan compensation of $1,973,624, and other compensation of $254,036. James E. Murray, Humana’s Executive Vice President and Chief Operating Officer earned total compensation of $6,722,630. He earned a base salary of $835,470, stock awards of $3,648,846, option awards $1,198,818, non-equity incentive plan compensation of $889,775, and other compensation of $149,721.

 

Choosing Between Humana Inc. (HUM) and Anthem, Inc. (ANTM)? – Economics and money

Humana Inc. (NYSE:HUM) and Anthem, Inc. (NYSE:ANTM) are both Healthcare companies that recently hit new highs. Many investors are wondering what to do with these names trading at such extreme levels. To determine if one is a better investment than the other, we will compare the two across growth, profitability, risk, return, dividends, and valuation measures.

Humana Inc. (NYSE:HUM) operates in the Health Care Plans segment of the Healthcare sector. The company has grown sales at a 8.10% annual rate over the past five years, putting it in the medium growth category. HUM has a net profit margin of 3.40% and is more profitable than the average company in the Health Care Plans industry. In terms of efficiency, HUM has an asset turnover ratio of 1.81. This figure represents the amount of revenue a company generates per dollar of assets. HUM’s financial leverage ratio is 1.94, which indicates that the company’s asset base is primarily funded by equity capital. Company’s return on equity, which is really just the product of the company’s profit margin, asset turnover, and financial leverage ratios, is 16.80%, which is better than the Health Care Plans industry average ROE.

Humana Inc. (HUM) pays out an annual dividend of 1.60 per share. At the current valuation, this equates to a dividend yield of 0.63%. The company has a payout ratio of 10.30%. HUM’s current dividend therefore should be sustainable. Stock’s free cash flow yield, which represents the amount of cash available to investors before dividends, expressed as a percentage of the stock price, is -0.74. All else equal, companies with higher FCF yields are viewed as cheaper. Company trades at a P/E ratio of 20.84, and is less expensive than the average stock in the Health Care Plans industry. The average investment recommendation for HUM, taken from a group of Wall Street Analysts, is 1.90, or a buy.

Over the past three months, Humana Inc. insiders have been net buyers, dumping a net of -60,399 shares. This implies that insiders have been feeling relatively bearish about the outlook for HUM. Insider activity and sentiment signals are important to monitor because they can shed light on how “risky” a stock is perceived to be at it’s current valuation. Knowing this, it makes sense to look at beta, a measure of market risk. HUM has a beta of 0.89 and therefore an below average level of market volatility.

Anthem, Inc. (NYSE:ANTM) operates in the Health Care Plans segment of the Healthcare sector. ANTM has increased sales at a 6.90% CAGR over the past five years, and is considered a medium growth stock. The company has a net profit margin of 3.30% and is more profitable than the average Health Care Plans player. ANTM’s asset turnover ratio is 1.32 and the company has financial leverage of 1.63. ANTM’s return on equity of 11.50% is worse than the Health Care Plans industry average.

Anthem, Inc. (ANTM) pays a dividend of 2.80, which translates to dividend yield of 1.34% based on the current price. Stock has a payout ratio of 23.40%. According to this ratio, ANTM should be able to continue making payouts at these levels. The company trades at a free cash flow yield of 3.59 and has a P/E of 18.91. Compared to the average company in the 23.79 space, ANTM is relatively cheap. The average analyst recommendation for ANTM is 2.10, or a buy.

Anthem, Inc. insiders have sold a net of -51,627 shares during the past three months, which implies that the company’s top executives have been feeling bearish about the stock’s outlook. Finally, ANTM’s beta of 0.77 indicates that the stock has an below average level of market risk.

Humana Inc. (NYSE:ANTM) scores higher than Anthem, Inc. (NYSE:HUM) on 7 of the 13 measures compared between the two companies. ANTM has the better fundamentals, scoring higher on leverage metrics.